Cocrystal Pharma, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.

Public ticker
COCP on Nasdaq
Latest financial report
15 May 2026
Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Bothell, WA
SEC filing record 1 source field available
Fiscal year end
31 December

Shareable Research Card

COCP - Cocrystal Pharma, Inc. Financial Facts

COCP - Cocrystal Pharma, Inc. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.

Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.

Context
Latest metrics period: Q1 2026
Latest reported value
Return On Equity -155%

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.

Open stable link Open latest 10-Q/10-K hub Which companies report the highest net income?

Return Loop

Why revisit this company facts page

Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.

Latest source-backed update
Latest metrics period Q1 2026
Why come back
Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
  • Current latest metrics period: Q1 2026.
  • Most recent SEC facts end date on this page: 31 Mar 2026.
  • Save this filer to return when the next filing-backed metric period changes the picture.

Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.

Create account to save this filer Open latest 10-Q/10-K hub

Latest update

Latest update for COCP - Cocrystal Pharma, Inc.

New fact period available

Latest financial period: Q1 2026. Reopen this facts page to verify the newest reported period against the prior baseline.

Update date

15 May 2026

Page type

Company facts

Latest period

Q1 2026

SEC-backed company facts were refreshed from filings filed on 15 May 2026.

Open recent updates hub Open latest 10-Q/10-K hub

Benchmark Context

How Return On Equity compares

Return On Equity is up about 46% versus the comparable prior period.

Compared with

Compared with Cocrystal Pharma, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.

Why this is notable

Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.

  • Latest comparable period on this page: Q1 2026.
  • Peer context will appear when enough companies report a comparable value for this metric.
  • Open the metric history first if you want to verify the exact period-to-period change.

Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.

Open NetIncomeLoss YoY history Which companies report the highest net income?

How to read key metrics on this page

These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.

Plain-English Guide

How to read Net Income on this page

Net income is profit after operating costs, interest, taxes, and other non-operating items.

Why people care

It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.

How to read it

Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.

Compare next

Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.

Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.

Open a live SEC-backed example

Open Net Income guide

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it

Key facts

  • COCP - Cocrystal Pharma, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q1 2026.
  • Headline metric: Return On Equity -155%.

Change

  • Return On Equity YoY change: +46%.
  • Most recent SEC facts end date: 31 Mar 2026.

Research use

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Evidence

Based on latest 10-Q/10-K

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.

View source filing

Latest SEC snapshot (2026-03-31) highlights Return On Equity -154.6%, Return On Assets -62.4%, and Operating Margin -1047.1%.

Valuation Snapshot

SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.

DCF value materially below price Overvalued Low confidence

-623%

fair value gap

Fair value per share

$7.52

Market price

$1.44

COCP - Local security

PEG ratio

n/a

Enterprise value

$110.75M

Equity value

$103.73M

DCF fair value scenarios

Bear

$5.49

Overvalued
Growth
1%
Discount
11%
Terminal
2%

Gap -481%

Base

$7.52

Overvalued
Growth
4%
Discount
10%
Terminal
2.5%

Gap -623%

Bull

$10.73

Overvalued
Growth
7%
Discount
9%
Terminal
3%

Gap -845%

Base growth: DCF Growth Assumption.

Key valuation metrics

EV/Revenue

57.0x

Local security market EV / SEC revenue

EV/EBITDA

n/a

Local security market EV / SEC EBITDA

Ebitda is unavailable or not positive

P/E

n/a

Local security market price / SEC EPS

Net income is unavailable or not positive

P/S

88.2x

Local security market cap / SEC revenue

P/B

4.8x

Local security market cap / SEC equity

PEG

n/a

P/E / DCF Growth Assumption

P/e or positive growth is unavailable

Core assumptions

Projection
5 years
FCF growth
4%
Discount rate
10%
Terminal growth
2.5%

SEC fact inputs

DCF base FCF
$7.6M
Trailing SEC FCF
Reported FCF
$7.6M
Net income
$8.83M
EBITDA
$8.99M
Cash
$7.02M
Debt
n/a
Equity
$4.12M
Shares
13,786,000

Data confidence notes

  • Dcf base free cash flow: dcf base starts from trailing sec free cash flow
  • Dcf base free cash flow: trailing free cash flow is not positive
  • Dcf confidence is low for this sec-only free cash flow estimate
  • Debt missing: equity value treats debt as 0
  • Base free cash flow is negative; dcf output is mechanically computed but high risk
  • Peg unavailable: earnings per share is not positive

Compare This Company Through SEC-backed Metrics

Use these links to compare COCP - Cocrystal Pharma, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

48.1/100

Caution Confidence medium

Return On Equity

-155%

Metric score 0.0/100

Return On Assets

-62%

Metric score 0.0/100

Financial Health

Current Ratio
2.66x
Quick Ratio
2.44x
Debt to Equity
0.35x

Strengths

Current Ratio, Debt-to-equity, and NetIncomeLoss YoY

Watchpoints

Return On Equity, Return On Assets, and Operating Margin

Key metrics snapshot

Profitability

Metric Latest value YoY change
Return On Equity -155% +46%
Return On Assets -62% +15%
Operating Margin -1047%

Financial Health

Metric Latest value YoY change
Current Ratio 2.66x -42%
Quick Ratio 2.44x
Debt-to-equity 0.35x

Growth

Metric Latest value YoY change
Revenues $225,000
NetIncomeLoss YoY 44%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 13,785,759 +36%
Common Stock, Shares, Outstanding 13,787,000 +36%
Common Stock, Value, Issued $13,000 +30%
Weighted Average Number of Shares Outstanding, Basic 13,786,000 +36%
Weighted Average Number of Shares Outstanding, Diluted 13,786,000 +36%

Supporting Metrics

These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.

Metric Latest value YoY change
Accounts Payable, Current $1,371,000 +70%
Assets $7,426,000 -30%
Assets, Current $5,939,000 -33%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,340,000 +20%
Common Stock, Par or Stated Value Per Share 0.001 0%
Common Stock, Shares Authorized 100,000,000 0%
Common Stock, Shares, Issued 13,787,000 +36%
Earnings Per Share, Basic -0.72 +54%
Earnings Per Share, Diluted -0.72 +54%
Employee-related Liabilities, Current $101,000 +1%
General and Administrative Expense $4,193,000 -18%
Income Tax Expense (Benefit) $0
Lessee, Operating Lease, Liability, to be Paid $1,619,000 -20%
Lessee, Operating Lease, Liability, to be Paid, Year One $415,000 -0.96%
Lessee, Operating Lease, Liability, to be Paid, Year Three $249,000 -34%
Lessee, Operating Lease, Liability, to be Paid, Year Two $376,000 -9.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $195,000 -34%
Liabilities $3,310,000 -1.3%
Liabilities and Equity $7,426,000 -30%
Liabilities, Current $2,229,000 +15%
Net Cash Provided by (Used in) Operating Activities $2,340,000 +20%
Nonoperating Income (Expense) $205,000 -3.3%
Operating Income (Loss) $9,034,000 +44%
Operating Lease, Liability $1,424,000 -18%
Operating Lease, Liability, Current $343,000 +11%
Operating Lease, Liability, Noncurrent $1,081,000 -24%
Operating Lease, Right-of-Use Asset $1,311,000 -19%
Operating Lease, Weighted Average Discount Rate, Percent 0.064 0%
Property, Plant and Equipment, Gross $2,094,000 +0.58%
Property, Plant and Equipment, Net $81,000 -36%
Research and Development Expense $5,066,000 -54%
Retained Earnings (Accumulated Deficit) $344,548,000 -2.6%
Share-based Payment Arrangement, Expense $272,000 -52%
Share-based Payment Arrangement, Noncash Expense $84,000 +2.4%
Stockholders' Equity Attributable to Parent $4,116,000 -44%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .